fenofibrate has been researched along with Prediabetic State in 4 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Prediabetic State: The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to investigate mechanisms of lipid metabolic inflexibility in human obesity and the ability of fenofibrate (FENO) to increase skeletal muscle fatty acid oxidation (FAO) in primary human skeletal muscle cell cultures (HSkMC) exhibiting metabolic inflexibility." | 9.24 | Metabolic Inflexibility with Obesity and the Effects of Fenofibrate on Skeletal Muscle Fatty Acid Oxidation. ( Boyle, KE; Friedman, JE; Houmard, JA; Janssen, RC; Rasouli, N; Underkofler, C, 2017) |
| "Our study included 41 fenofibrate-treated patients with impaired glucose tolerance allocated to either metformin (3 g daily) or placebo." | 9.17 | Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "The study involved a group of 242 metabolic syndrome patients with or without pre-diabetes and randomized to atorvastatin, fenofibrate, or placebo." | 9.14 | Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. ( Bachowski, R; Gdula-Dymek, A; Krysiak, R; Okopien, B, 2010) |
| "This study was designed to investigate mechanisms of lipid metabolic inflexibility in human obesity and the ability of fenofibrate (FENO) to increase skeletal muscle fatty acid oxidation (FAO) in primary human skeletal muscle cell cultures (HSkMC) exhibiting metabolic inflexibility." | 5.24 | Metabolic Inflexibility with Obesity and the Effects of Fenofibrate on Skeletal Muscle Fatty Acid Oxidation. ( Boyle, KE; Friedman, JE; Houmard, JA; Janssen, RC; Rasouli, N; Underkofler, C, 2017) |
| "Our study included 41 fenofibrate-treated patients with impaired glucose tolerance allocated to either metformin (3 g daily) or placebo." | 5.17 | Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "The study involved a group of 242 metabolic syndrome patients with or without pre-diabetes and randomized to atorvastatin, fenofibrate, or placebo." | 5.14 | Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. ( Bachowski, R; Gdula-Dymek, A; Krysiak, R; Okopien, B, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Krysiak, R | 2 |
| Gdula-Dymek, A | 2 |
| Okopień, B | 2 |
| Boyle, KE | 1 |
| Friedman, JE | 1 |
| Janssen, RC | 1 |
| Underkofler, C | 1 |
| Houmard, JA | 1 |
| Rasouli, N | 1 |
| Bachowski, R | 1 |
| Wan, Q | 1 |
| Wang, F | 2 |
| Guan, Q | 1 |
| Liu, Y | 1 |
| Wang, C | 1 |
| Feng, L | 1 |
| Gao, G | 1 |
| Gao, L | 1 |
| Zhao, J | 1 |
4 trials available for fenofibrate and Prediabetic State
| Article | Year |
|---|---|
Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance.
Topics: Dose-Response Relationship, Drug; Drug Synergism; Female; Fenofibrate; Fibrinogen; Glucose Intoleran | 2013 |
Metabolic Inflexibility with Obesity and the Effects of Fenofibrate on Skeletal Muscle Fatty Acid Oxidation.
Topics: Adolescent; Adult; Aged; Cells, Cultured; Fatty Acids; Female; Fenofibrate; Humans; Lipid Metabolism | 2017 |
Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cytokines; Factor VII; Fenofibrate; Fibr | 2010 |
Regression to normoglycaemia by fenofibrate in pre-diabetic subjects complicated with hypertriglyceridaemia: a prospective randomized controlled trial.
Topics: Adolescent; Adult; Aged; Blood Glucose; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypoglyce | 2010 |